LobbyingOncology Nursing Society lobbying by quarter
Oncology Nursing Society's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Oncology Nursing Society
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $60K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $108.3K | 2 |
| Q1 2023 | $114.3K | 2 |
| Q2 2023 | $101K | 2 |
| Q3 2023 | $67K | 2 |
| Q4 2023 | $93.7K | 2 |
| Q1 2024 | $85K | 2 |
| Q2 2024 | $80K | 2 |
| Q3 2024 | $67.5K | 2 |
| Q4 2024 | $20K | 2 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $20K | 1 |
| Q3 2025 | $20K | 1 |
| Q4 2025 | $20K | 1 |
| Q1 2026 | $20K | 1 |
| Q2 2026 | $20K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$856.7K · 23 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES23 reports
- SENATE23 reports
- Health & Human Services, Dept of (HHS)8 reports
- Health Resources & Services Administration (HRSA)8 reports
- White House Office7 reports
- Natl Institutes of Health (NIH)6 reports
- Food & Drug Administration (FDA)5 reports
- Centers For Disease Control & Prevention (CDC)3 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseOncology Nursing Society | $556.7K | 9 quarters |
| Hart Health Strategies | $300K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SUSAN RAMTHUN | Senator Bill Frist | Q2 2026 |
| VICKI HART | Senator Bob Dole; Senator Trent Lott | Q2 2026 |
| ALEC STONE | Clinton White House, Women's Health Initiatives | Q3 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Hart Health Strategies | $20K |
| 04/20for Q1 | Hart Health Strategies | $20K |
| 01/16for Q4 2025 | Hart Health Strategies | $20K |
| 25/10/20for Q3 2025 | Hart Health Strategies | $20K |
| 25/07/10for Q2 2025 | Hart Health Strategies | $20K |
| 25/04/18for Q1 2025 | Hart Health Strategies | $20K |
| 25/03/05for Q4 2024 | In-house | Under $5,000 |
| 25/01/16for Q4 2024 | In-house | $41.2K |
| 25/01/05for Q4 2024 | Hart Health Strategies | $20K |
| 24/10/18for Q3 2024 | In-house | $47.5K |
| 24/10/10for Q3 2024 | Hart Health Strategies | $20K |
| 24/07/21for Q2 2024 | Hart Health Strategies | $20K |
| 24/07/15for Q2 2024 | In-house | $60K |
| 24/04/22for Q1 2024 | Hart Health Strategies | $20K |
| 24/04/18for Q1 2024 | In-house | $65K |
| 24/01/19for Q4 2023 | Hart Health Strategies | $20K |
| 24/01/19for Q4 2023 | In-house | $73.7K |
| 23/10/21for Q3 2023 | Hart Health Strategies | $20K |
| 23/10/17for Q3 2023 | In-house | $47K |
| 23/07/19for Q2 2023 | In-house | $81K |